Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico

Table 2

Complications, response rate, and survival by treatment regimen.

	RCHOP	RChOP	RCOP	value
(%)	53 (100)	48 (100)	40 (100)	—
Complications of treatment
Infections	—	—	—
None	18 (33.96)	14 (29.17)	23 (57.5)	0.09
Ambulatory treated	15 (22.64)	12 (25.0)	10 (25)
Febrile neutropenia (FN)	12 (22.64)	11 (22.92)	4 (10)
Other than FN, requiring hospitalization	8 (15.09)	11 (22.92)	3 (7.5)
Myelosuppression	—	—	—
None	36 (67.92)	30 (62.5)	26 (65)	0.94
No transfusion required	6 (11.32)	8 (16.67)	5 (12.5)
Required transfusion	11 (20.75)	10 (20.83)	9 (22.5)
Other complications (G III-IV)	—	—	—
None	28 (52.83)	17 (35.42)	24 (60)	0.359
Pain	3 (5.66)	4 (8.33)	2 (5)
2nd malignancy	0	1 (2.08)	0
Neuropathy	1 (1.89)	5 (10.42)	2 (5)
Lung	0	1 (2.08)	0
Thrombosis	1 (1.89)	3 (6.25)	0
Cardiovascular	8 (15.09)	5 (10.42)	6 (15)
Gastrointestinal	8 (15.09)	5 (10.42)	6 (15)
Renal	4 (7.55)	7 (14.58)	2 (5)
Required radiotherapy	22 (41.51)	17 (35.42)	18 (45)	0.065
Response	—	—	—
Complete	35 (66.04)	30 (62.5)	21 (52.5)
Partial	6 (11.32)	3 (6.25)	3 (7.5)	0.418
Stable disease	0	0	1 (2.5)
Progressive disease	2 (3.77)	6 (12.5)	3 (7.5)
Not evaluated	10 (18.87)	9 (18.75)	12 (30)
Relapsed	6 (11.32)	6 (12.5)	7 (17.5)	0.668
Mean disease-free survival (95% IC)	34.72 (29.54–39.89)	27.77 (22.28–33.25)	24.99 (18.9–31.09)	>0.05
Mean overall survival (95% IC)	35.8 (30.56–41.05)	27.69 (22.18–33.2)	44.29 (32.65–55.93)	>0.05

Restricted mean.